文献速递炎症性肠病

乌司奴单抗与抗肿瘤坏死因子α治疗储袋克罗恩样疾病的前瞻性比较

A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the Pouch.
PubMed 文献 · Am J Gastroenterol · 2025-06-25

这项前瞻性多中心队列研究纳入132例慢性储袋炎或储袋克罗恩样疾病(CLDP)患者,比较乌司奴单抗与抗TNF治疗6个月临床缓解率。CLDP患者中乌司奴单抗组缓解率62% vs 抗TNF组40%(P=0.027),但校正后比值比无独立统计学意义(aOR 1.91,95%CI 0.69-5.30);慢性储袋炎患者两组无显著差异(P=0.946)。

要点

  • CLDP患者乌司奴单抗6个月临床缓解率62%,抗TNF组40%(P=0.027)。
  • 校正混杂后CLDP患者缓解比值比无独立统计学意义(aOR 1.91,95%CI 0.69-5.30)。
  • 慢性储袋炎患者两组6个月临床缓解无显著差异(P=0.946)。

核心结论

  • 这些数据提示乌司奴单抗在CLDP患者中可能获益,应推动该人群未来开展新的有效性评估。

研究设计与样本

  • 前瞻性多中心队列研究,纳入132例开始抗TNF治疗或乌司奴单抗治疗的慢性储袋炎和CLDP患者。
  • 132例中106例(80%)诊断为CLDP,82例(62%)启动乌司奴单抗治疗。

主要发现

  • CLDP患者中乌司奴单抗组6个月临床缓解率62% vs 抗TNF组40%(P=0.027)。
  • 慢性储袋炎患者中两组6个月临床缓解无显著差异(P=0.946)。
  • 校正瘘管存在、术前先进治疗数量及IPAA后先进治疗数量后,CLDP患者乌司奴单抗相比抗TNF的6个月缓解比值比无独立统计学意义(aOR 1.91,95%CI 0.69-5.30)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Many patients with chronic pouchitis and Crohn's-like disease of the pouch (CLDP) are treated with biologics; however, the comparative effectiveness of advanced therapies in this population has not been systematically evaluated. We sought to compare the effectiveness of antitumor necrosis factor α (anti-TNF) therapies and ustekinumab in patients with chronic inflammatory conditions of the pouch. METHODS: We conducted a prospective, multicenter, cohort study. We included patients with chronic pouchitis and CLDP initiating treatment with anti-TNF therapies or ustekinumab. The primary outcome was clinical remission at 6 months after induction. We also evaluated clinical remission at 6 months among patients with chronic pouchitis and CLDP separately. RESULTS: Among 132 patients, 106 (80%) had a diagnosis of CLDP and 82 (62%) initiated therapy with ustekinumab. A significantly higher proportion of patients with CLDP treated with ustekinumab were in clinical remission at 6 months as compared with patients treated with anti-TNF therapy (62% vs 40%, P = 0.027); however, there was no significant difference among patients with chronic pouchitis ( P = 0.946). There was no independent statistical significance in the odds of remission at 6 months among patients with CLDP among patients receiving ustekinumab compared with anti-TNF therapy (adjusted odds ratio 1.91, 95% confidence interval 0.69-5.30) after adjusting for presence of a fistula, number of preoperative advanced therapies, and number of advanced therapies after IPAA. DISCUSSION: These data suggest the potential benefit of ustekinumab in patients with CLDP and should prompt future novel effectiveness evaluations in this population.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Barnes EL, Raffals L, Qazi T, et al. A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the Pouch. Am J Gastroenterol. 2025. PMID: 40560215. doi:10.14309/ajg.0000000000003608

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。